ArticleCureus2025
Salvage Radiosurgery After Brachytherapy for Locally Recurrent Prostate Cancer With Real-Time Adaptive Motion Management Using Previously Implanted Brachytherapy Seeds as Fiducial Markers.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Locally recurrent prostate cancer after radiotherapy is a difficult clinical scenario. Focal therapy with stereotactic body radiation therapy (SBRT) is a promising treatment option. In this case report, we present the case of a male patient who underwent low dose rate (LDR) brachytherapy many years ago and experienced a prostate-specific membrane antigen positron emission tomography (PSMA PET) avid local recurrence of prostate cancer with rising prostate-specific antigen (PSA). He was able to undergo salvage CyberKnife (Accuray, Madison, WI) robotic radiosurgery without the need for additional fiducial marker placement by tracking previously implanted brachytherapy seeds. Treatment of 40 Gy in five fractions to the PET avid tumor gross tumor volume (GTV) and 35 Gy in five fractions to the planning target volume (PTV) was successfully delivered with minimal toxicity. The patient tolerated therapy well with excellent urinary and sexual functioning and declining PSA at the last follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.